Background Metabolic syndrome and dyslipidemia contribute to the development of a pro-
inflammatory state in asthma. However, studies investigating the association between …

Even if severe asthma (SA) accounts for 5–10% of all cases of the disease, it is currently a
crucial unmet need, owing its difficult clinical management and its high social costs. For this …

Objectives We reviewed the phenotyping and endotyping of chronic rhinosinusitis (CRS)
and treatment options. Methods We searched PubMed, Google, Google Scholar, and the …

Severe asthma has a substantial epidemiological impact on children and biological
treatments can be an option to take into account, as they target specific molecules and …

Severe asthma is a discrete clinical entity characterised by recurrent exacerbations, reduced
quality of life and poor asthma control as ordinary treatment regimens remain inadequate …

Omalizumab is the first monoclonal antibody that was globally approved as a personalized
treatment option for patients with moderate-to-severe allergic asthma. This review …

Omalizumab is a monoclonal anti-IgE antibody that has been used to treat allergic asthma
for over a decade. The use of omalizumab to treat other diseases has largely been limited to …

Severe asthma is a chronic and heterogeneous disease that negatively affects the quality of
life of our patients and health care utilization. Given the remaining burden of uncontrolled …

Severe asthma is a complex multifactorial disease that requires specialist multidisciplinary
input for optimal clinical outcomes. Following multidimensional assessment for optimisation …

The critical role played by IgE in allergic asthma is well-documented and clinically
precedented, but some patients in whom IgE neutralization may still offer clinical benefit are …